Use of an antibody or antigen binding fragment comprising an antigen-binding region that binds specifically to a protein having the amino acid sequence of SEQ ID NO: 10 in the manufacture of a medicament suitable for administration to a mammalian subject for the treatment of a disease selected from the group consisting of ductal-adenocarcinoma, infiltrating ductal carcinoma, lobular carcinoma, mucinous adenocarcinoma, intra duct and invasive ductal carcinoma, Scirrhous adenocarcinoma, Moderate to Poorly Differentiated Adenocarcinoma of the cecum, Well, Moderate and Poorly Differentiated Adenocarcinoma of the colon, Tubular adenocarcinoma, Grade 2 Tubular adenocarcinoma of the ascending colon, colon adenocarcinoma Duke’s stage C1, invasive adenocarcinoma, Adenocarcinoma of the rectum, Grade 3 Adenocarcinoma of the rectum, Moderately Differentiated Adenocarcinoma of the rectum, Moderately Differentiated Mucinous adenocarcinoma of the rectum, Well to Poorly differentiated Non-small cell carcinoma, Squamous Cell Carcinoma, Moderately Differentiated Squamous Cell Carcinoma, Moderately to poorly differentiated squamous carcinoma, Moderately well differentiated keratinising squamous cell carcinoma, large cell adenocarcinoma, Small cell lung cancer, Adenocarcinoma Gleason Grade 5 to 9, Infiltrating adenocarcinoma, High grade prostatic intraepithelial neoplasia, undifferentiated carcinoma, moderately differentiated gastric adenocarcinoma, serous papillary cystic carcinoma, Serous cystadenocarcinoma, Invasive serous papillary carcinoma, Glioblastoma multiforme, Astrocytoma, Astrocytoma grade 4, Clear cell renal cell carcinoma, Hepatocellular carcinoma, Low Grade hepatocellular carcinoma, Fibrolamellar Hepatocellular Carcinoma, large cell lymphoma, and High and low grade Non-Hodgkin’s Lymphoma； with the proviso that if the cancer is ovarian cancer, it is not Granulosa cell tumor of the ovary and with the proviso that if the cancer is brain cancer, it is not Astrocytoma grade 2
